Literature DB >> 32726073

The Alpha-1 Antitrypsin Polymer Load Correlates With Hepatocyte Senescence, Fibrosis Stage and Liver-Related Mortality.

Marianna Mela1, Wendy Smeeton1, Susan E Davies2, Elena Miranda3, Cinzia Scarpini4, Nick Coleman4, Graeme J M Alexander5.   

Abstract

BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is an important, inherited cause of chronic liver disease. Marked variation in fibrosis stages in patients with homozygous deficiency and those factors that determine whether heterozygous carriers develop liver fibrosis, remain unexplained. Murine studies implicate polymerized alpha-1 antitrypsin (AAT) within hepatocytes as pathogenic. AIMS AND METHODS: The relationship between the quantity of polymerized AAT within hepatocytes (polymer load), stage of hepatic fibrosis and liver-related clinical outcomes (death, evolution to hepatocellular carcinoma, or need for liver transplantation) were investigated using liver tissue from 92 patients at first presentation with either homozygous or heterozygous AATD. Further tissue-based studies were undertaken to determine if polymerized AAT was associated with failure of cell cycle progression, accelerated aging or hepatocyte senescence by immunohistochemical analysis.
RESULTS: The AAT polymer load correlated closely with hepatic fibrosis stage and long-term clinical outcome, independent of homozygous or heterozygous status. AAT polymers within hepatocytes correlated closely with failure of cell cycle progression assessed using cell cycle phase markers, accelerated aging manifest as shortened telomeres and other markers consistent with hepatocyte senescence manifest as the presence of nuclear p21 expression and enlarged nuclei. The proportion of p21 positive hepatocytes or hepatocytes with enlarged nuclei correlated with hepatic fibrosis stage and the long-term clinical outcome.
CONCLUSION: These data suggest that accumulation of AAT polymers within hepatocytes drives senescence. Quantitation of both the AAT polymer load or hepatocyte senescence markers correlated with hepatic fibrosis stage and the long-term clinical outcome. Either or both could be considered markers of disease severity and treatment response in clinical trials. JCOPDF
© 2020.

Entities:  

Keywords:  alpha-1 antitrypsin; liver fibrosis; polymer load; polymers; senescence

Year:  2020        PMID: 32726073      PMCID: PMC7857716          DOI: 10.15326/jcopdf.7.3.2019.0158

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  27 in total

Review 1.  DNA damage checkpoints in stem cells, ageing and cancer.

Authors:  Tobias Sperka; Jianwei Wang; K Lenhard Rudolph
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09       Impact factor: 94.444

2.  Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

Authors:  Pavel Strnad; Stephan Buch; Karim Hamesch; Jochen Hampe; Thomas Berg; Christian Trautwein; Janett Fischer; Jonas Rosendahl; Renate Schmelz; Stefan Brueckner; Mario Brosch; Carolin V Heimes; Vivien Woditsch; David Scholten; Hans Dieter Nischalke; Sabina Janciauskiene; Mattias Mandorfer; Michael Trauner; Michael J Way; Andrew McQuillin; Matthias C Reichert; Marcin Krawczyk; Markus Casper; Frank Lammert; Felix Braun; Witigo von Schönfels; Sebastian Hinz; Greta Burmeister; Claus Hellerbrand; Andreas Teufel; Alexandra Feldman; Joern M Schattenberg; Heike Bantel; Anita Pathil; Muenevver Demir; Johannes Kluwe; Tobias Boettler; Monika Ridinger; Norbert Wodarz; Michael Soyka; Marcella Rietschel; Falk Kiefer; Thomas Weber; Silke Marhenke; Arndt Vogel; Holger Hinrichsen; Ali Canbay; Martin Schlattjan; Katharina Sosnowsky; Christoph Sarrazin; Johann von Felden; Andreas Geier; Pierre Deltenre; Bence Sipos; Clemens Schafmayer; Michael Nothnagel; Elmar Aigner; Christian Datz; Felix Stickel; Marsha Yvonne Morgan
Journal:  Gut       Date:  2018-08-01       Impact factor: 23.059

3.  Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation.

Authors:  Karim Hamesch; Mattias Mandorfer; Vítor M Pereira; Linda S Moeller; Monica Pons; Grace E Dolman; Matthias C Reichert; Carolin V Schneider; Vivien Woditsch; Jessica Voss; Cecilia Lindhauer; Malin Fromme; Igor Spivak; Nurdan Guldiken; Biaohuan Zhou; Anita Arslanow; Benedikt Schaefer; Heinz Zoller; Elmar Aigner; Thomas Reiberger; Martin Wetzel; Britta Siegmund; Carolina Simões; Rui Gaspar; Luís Maia; Dalila Costa; Mário Bento-Miranda; Josef van Helden; Eray Yagmur; Danilo Bzdok; Jan Stolk; Wolfgang Gleiber; Verena Knipel; Wolfram Windisch; Ravi Mahadeva; Robert Bals; Rembert Koczulla; Miriam Barrecheguren; Marc Miravitlles; Sabina Janciauskiene; Felix Stickel; Frank Lammert; Rodrigo Liberal; Joan Genesca; William J Griffiths; Michael Trauner; Aleksander Krag; Christian Trautwein; Pavel Strnad
Journal:  Gastroenterology       Date:  2019-05-20       Impact factor: 22.682

Review 4.  The discovery of α1-antitrypsin and its role in health and disease.

Authors:  Sabina M Janciauskiene; Robert Bals; Rembert Koczulla; Claus Vogelmeier; Thomas Köhnlein; Tobias Welte
Journal:  Respir Med       Date:  2011-03-01       Impact factor: 3.415

5.  Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants.

Authors:  T Sveger
Journal:  N Engl J Med       Date:  1976-06-10       Impact factor: 91.245

6.  A novel monoclonal antibody to characterize pathogenic polymers in liver disease associated with alpha1-antitrypsin deficiency.

Authors:  Elena Miranda; Juan Pérez; Ugo I Ekeowa; Nedim Hadzic; Noor Kalsheker; Bibek Gooptu; Bernard Portmann; Didier Belorgey; Marian Hill; Susan Chambers; Jeff Teckman; Graeme J Alexander; Stefan J Marciniak; David A Lomas
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

7.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson; J Carlson; R Velez
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

8.  Α₁-antitrypsin PiMZ heterozygosity has an independent aggravating effect on liver fibrosis in alcoholic liver disease.

Authors:  Diane Goltz; Kanishka Hittetiya; Lena Marie Vössing; Jutta Kirfel; Ulrich Spengler; Hans-Peter Fischer
Journal:  Virchows Arch       Date:  2014-07-29       Impact factor: 4.064

9.  Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver.

Authors:  Suman Verma; Phaedra Tachtatzis; Sue Penrhyn-Lowe; Cinzia Scarpini; Diana Jurk; Thomas Von Zglinicki; Nick Coleman; Graeme J M Alexander
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

Review 10.  Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Authors:  Jennifer A Dickens; David A Lomas
Journal:  Drug Des Devel Ther       Date:  2011-08-17       Impact factor: 4.162

View more
  2 in total

1.  Role of Hepatocyte Senescence in the Activation of Hepatic Stellate Cells and Liver Fibrosis Progression.

Authors:  Pramudi Wijayasiri; Stuart Astbury; Philip Kaye; Fiona Oakley; Graeme J Alexander; Timothy J Kendall; Aloysious D Aravinthan
Journal:  Cells       Date:  2022-07-17       Impact factor: 7.666

2.  Association between circulating alpha-1 antitrypsin polymers and lung and liver disease.

Authors:  Alexa Núñez; Irene Belmonte; Elena Miranda; Miriam Barrecheguren; Georgina Farago; Eduardo Loeb; Mònica Pons; Francisco Rodríguez-Frías; Pablo Gabriel-Medina; Esther Rodríguez; Joan Genescà; Marc Miravitlles; Cristina Esquinas
Journal:  Respir Res       Date:  2021-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.